Finch Therapeutics Group, Inc. (FNCH)
NASDAQ: FNCH · IEX Real-Time Price · USD
2.250
-0.240 (-9.64%)
At close: May 3, 2024, 3:59 PM
2.170
-0.080 (-3.56%)
After-hours: May 3, 2024, 7:06 PM EDT
Finch Therapeutics Group Revenue
In the year 2023, Finch Therapeutics Group had annual revenue of $107.00K, a decrease of -87.57%.
Revenue (ttm)
$107.00K
Revenue Growth
-87.57%
P/S Ratio
34.52
Revenue / Employee
$107,000
Employees
1
Market Cap
3.69M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 107.00K | -754.00K | -87.57% |
Dec 31, 2022 | 861.00K | -17.67M | -95.35% |
Dec 31, 2021 | 18.53M | 10.81M | 140.08% |
Dec 31, 2020 | 7.72M | -2.44M | -23.98% |
Dec 31, 2019 | 10.15M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionFNCH News
- 11 months ago - Finch Announces Reverse Stock Split of Common Stock - GlobeNewsWire
- 1 year ago - Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates - GlobeNewsWire
- 1 year ago - Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement - GlobeNewsWire
- 1 year ago - Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates - GlobeNewsWire
- 1 year ago - Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets - GlobeNewsWire
- 1 year ago - Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results - GlobeNewsWire
- 1 year ago - Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference - GlobeNewsWire
- 1 year ago - Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD - GlobeNewsWire